Daniel A. Finan, Ph.D., is a research director at JDRF, responsible for the strategy and management of the Artificial Pancreas (AP) and Glucose Control (GC) programs. In the AP portfolio, he targets three key objectives: (1) improving outcomes for people with type 1 diabetes (T1D), (2) reducing the burden from both on-body (e.g., miniaturization of devices) and user-experience (e.g., increased automation) perspectives, and (3) expanding affordable access to and adoption of AP technologies. In the GC portfolio, he is in charge of strategies around novel insulin therapies like glucose-responsive insulin (GRI) and liver-targeted insulin (LTI), as well as non-insulin treatments like GLP-1 agonists and SGLT inhibitors.

Dr. Finan brings his technological and device development expertise to JDRF. Prior to joining in 2017, he was a senior principal algorithm scientist at Animas, a Johnson & Johnson company. He was responsible for overseeing the development, validation, clinical investigation and implementation of the control algorithm of Animas’ artificial pancreas program. Dr. Finan also investigated innovative approaches to algorithms across their various devices and tools.

Dr. Finan trained as a chemical engineer, both in his bachelor’s degree at the University of Colorado Boulder and in his doctorate at the University of California, Santa Barbara. He did his postdoctoral training at the Technical University of Denmark, where he investigated advanced control strategies for artificial pancreas applications for type 1 diabetes.